Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation

Transplantation

Volumn 62, Issue 7, 1996, Pages 920-926

  Kershner, Ronald P ^a   Fitzsimmons, William E ^a  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TACROLIMUS;

EID: 0029849460     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199610150-00009     Document Type: Article

References (19)

1. Takahara S, Kokado Y, Kameoka H, et al. Monitoring of FK506 blood levels in kidney transplant recipients. Transplant Proc 1994; 26: 2106.
2. Japanese FK506 Study Group. Japanese study of FK506 kidney transplantation: the benefit of monitoring the whole blood FK506 concentration. Transplant Proc 1991; 23: 3085.
3. Japanese FK506 Study Group. Japanese study of FK506 on kidney transplantation: results of an early phase II study. Transplant Proc 1991; 23: 3071.
4. Winkler M, Ringe B, Rodeck B, et al. The use of plasma levels for FK506 dosing in liver-grafted patients. Transpl Int 1994; 7: 329.
5. Bäckman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Transplantation 1994; 57: 519.
6. Erden E, Warty V, Magnone M, Shapiro R, Demetris J, Randhawa P. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection [Letter]. Transplantation 1994; 58: 397.
7. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
8. U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
9. Schwartz M, Holst B, Facklam D, Buell D. The US Multicenter FK 506 Dose Optimization Study Group. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. Transplant Proc 1995; 27: 1107.
10. Vincenti F, Bretan P, Melzer J, et al. Analysis of the incidence and outcome of acute rejection in FK506 treated renal transplant recipients: results of a concentration controlled trial. Proceedings of the 19th annual scientific meeting of the American Society of Transplant Surgeons, May 1993.
11. Kobayashi M, Tamura K, Katayama N, et al. FK506 assay past and present - characteristics of FK506 ELISA. Transplant Proc 1991; 23: 2725.
12. Jusko WJ, D'Ambrosio R. Monitoring FK506 concentrations in plasma and whole blood. Transplant Proc 1991; 23: 2732.
13. ® analyzer. Transplant Proc 1991; 23: 2748.
14. Abbott RD. Logistic regression in survival analysis. Am J Epidemiol 1985; 121: 465.
15. Winkler M, Ringe B, Baumann J, Loss M, Wonigeit K, Pichlmayr R. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK506 for immunosuppression. Clin Chem 1994; 40: 2247.
16. McMaster P, Mirza DF, Ismail T, Vennarecci G, Patapis P, Mayer AD. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995; 17: 602.
17. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17: 606.
18. Todo S, Fung JJ, Starzl TE, et al. Liver, kidney and thoracic organ transplantation under FK506. Ann Surg 1990; 212: 295.
19. Starzl TE, Abu-Elmagd K, Tzakis A, Fung JJ, Porter KA, Todo S. Selected topic on FK506: with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practial pharmacokinetics. Transplant Proc 1991; 23: 914.